New drug aims to fight skin cancer in transplant patients
NCT ID NCT07100925
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a drug called tolododekin alfa (ANK-101) given before surgery to kidney transplant recipients with high-risk skin cancer. The goal was to see if the drug could reduce the number of cancer cells in the removed tissue. However, the trial was withdrawn before any patients were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tolododekin alfa (ANK-101)
What this could lead to
If it works, this could point toward a treatment that helps kidney transplant patients with high-risk skin cancer respond better to surgery.
What could go wrong
This trial was withdrawn before any participants were enrolled, so there is no data yet. It is a very early Phase 1 study, and the approach may not prove effective or safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.